Detalhe da pesquisa
1.
Rusfertide, a Hepcidin Mimetic, for Control of Erythrocytosis in Polycythemia Vera.
N Engl J Med
; 390(8): 723-735, 2024 Feb 22.
Artigo
em Inglês
| MEDLINE | ID: mdl-38381675
2.
Genetic landscape and clinical outcomes of patients with BCOR mutated myeloid neoplasms.
Haematologica
; 109(6): 1779-1791, 2024 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38299584
3.
Reappraisal of mast cell leukemia based on a single institution review of 16 cases: Mast cell morphology determines clinical outcome.
Am J Hematol
; 99(1): E1-E4, 2024 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-37688525
4.
Venetoclax and hypomethylating agent combination therapy in newly diagnosed acute myeloid leukemia: Genotype signatures for response and survival among 301 consecutive patients.
Am J Hematol
; 99(2): 193-202, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38071734
5.
Venetoclax duration (14 vs. 21 vs. 28 days) in combination with hypomethylating agent in newly diagnosed acute myeloid leukemia: Comparative analysis of response, toxicity, and survival.
Am J Hematol
; 99(2): E63-E66, 2024 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-38100217
6.
Meaningful Symptomatic Change in Patients With Myelofibrosis From the SIMPLIFY Studies.
Value Health
; 27(5): 607-613, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38311180
7.
Phase 1/1b study of azacitidine and hedgehog pathway inhibitor sonidegib in patients with myeloid neoplasms.
Cancer
; 129(15): 2321-2330, 2023 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37042080
8.
A phase II study of combination daunorubicin, cytarabine (Ara-c), and nilotinib (TAsigna) (DATA) in patients newly diagnosed with acute myeloid leukemia with KIT expression.
Am J Hematol
; 98(3): 472-480, 2023 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-36625066
9.
Phase 1 study of anti-CD47 monoclonal antibody CC-90002 in patients with relapsed/refractory acute myeloid leukemia and high-risk myelodysplastic syndromes.
Ann Hematol
; 101(3): 557-569, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34981142
10.
Supportive Care for Patients with Lymphoma Undergoing CAR-T-cell Therapy: the Advanced Practice Provider's Perspective.
Curr Oncol Rep
; 24(12): 1863-1872, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36336769
11.
Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis.
Br J Haematol
; 195(3): 429-432, 2021 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-34254289
12.
Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
Am J Hematol
; 96(7): 781-789, 2021 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33844862
13.
Indications for Hematopoietic Cell Transplantation and Immune Effector Cell Therapy: Guidelines from the American Society for Transplantation and Cellular Therapy.
Biol Blood Marrow Transplant
; 26(7): 1247-1256, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32165328
14.
Choosing a Reduced-Intensity Conditioning Regimen for Allogeneic Stem Cell Transplantation, Fludarabine/Busulfan versus Fludarabine Melphalan: A Systematic Review and Meta-Analysis.
Biol Blood Marrow Transplant
; 25(4): 728-733, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30471339
15.
High-Dose Chemotherapy with Early Autologous Stem Cell Transplantation Compared to Standard Dose Chemotherapy or Delayed Transplantation in Patients with Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-Analysis.
Biol Blood Marrow Transplant
; 25(2): 239-247, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30244101
16.
Patient Perspectives Regarding Allogeneic Bone Marrow Transplantation in Myelofibrosis.
Biol Blood Marrow Transplant
; 25(2): 398-402, 2019 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-30292010
17.
Assessment of Quality of Life following Allogeneic Stem Cell Transplant for Myelofibrosis.
Biol Blood Marrow Transplant
; 25(11): 2267-2273, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31288096
18.
Organ Changes Associated with Provider-Assessed Responses in Patients with Chronic Graft-versus-Host Disease.
Biol Blood Marrow Transplant
; 25(9): 1869-1874, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31085305
19.
The Chronic Graft-versus-Host Disease Failure-Free Survival (cGVHD-FFS) Index.
Biol Blood Marrow Transplant
; 25(12): 2468-2473, 2019 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-31394265
20.
An endpoint associated with clinical benefit after initial treatment of chronic graft-versus-host disease.
Blood
; 130(3): 360-367, 2017 07 20.
Artigo
em Inglês
| MEDLINE | ID: mdl-28495794